Lobb RR[au] - Search Results

Year	Number of Results
1975	1
1976	2
1979	1
1980	1
1984	2
1985	9
1986	6
1987	1
1988	4
1989	1
1990	1
1991	3
1992	3
1993	2
1994	4
1995	5
1996	3
1997	3
1998	4
1999	9
2000	9
2001	3
2002	6
2003	4
2004	4
2005	2
2007	2
2012	1
2015	2
2019	2
2021	3
2022	1

1

Pathophysiologic role of alpha 4 integrins in the lung.

Lobb RR, Abraham WM, Burkly LC, Gill A, Ma W, Knight JA, Leone DR, Antognetti G, Pepinsky RB. Lobb RR, et al. Ann N Y Acad Sci. 1996 Oct 31;796:113-23. doi: 10.1111/j.1749-6632.1996.tb32573.x. Ann N Y Acad Sci. 1996. PMID: 8906218 Review.

2

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.

Ambrose C, Su L, Wu L, Dufort FJ, Sanford T, Birt A, Hackel BJ, Hombach A, Abken H, Lobb RR, Rennert PD. Ambrose C, et al. Among authors: lobb rr. PLoS One. 2021 Mar 18;16(3):e0247701. doi: 10.1371/journal.pone.0247701. eCollection 2021. PLoS One. 2021. PMID: 33735268 Free PMC article.

3

Purification of heparin-binding growth factors.

Lobb RR, Harper JW, Fett JW. Lobb RR, et al. Anal Biochem. 1986 Apr;154(1):1-14. doi: 10.1016/0003-2697(86)90487-2. Anal Biochem. 1986. PMID: 3518534 Review. No abstract available.

4

The leukocyte beta 1 integrins.

Hemler ME, Lobb RR. Hemler ME, et al. Among authors: lobb rr. Curr Opin Hematol. 1995 Jan;2(1):61-7. doi: 10.1097/00062752-199502010-00009. Curr Opin Hematol. 1995. PMID: 9371973 Review.

5

Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo.

Rennert PD, Dufort FJ, Su L, Sanford T, Birt A, Wu L, Lobb RR, Ambrose C. Rennert PD, et al. Among authors: lobb rr. Mol Cancer Ther. 2021 Oct;20(10):2071-2081. doi: 10.1158/1535-7163.MCT-20-1030. Epub 2021 Jul 12. Mol Cancer Ther. 2021. PMID: 34253594

6

Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design.

Klesmith JR, Wu L, Lobb RR, Rennert PD, Hackel BJ. Klesmith JR, et al. Among authors: lobb rr. Biochemistry. 2019 Dec 3;58(48):4869-4881. doi: 10.1021/acs.biochem.9b00808. Epub 2019 Nov 21. Biochemistry. 2019. PMID: 31702909

7

The pathophysiologic role of alpha 4 integrins in vivo.

Lobb RR, Hemler ME. Lobb RR, et al. J Clin Invest. 1994 Nov;94(5):1722-8. doi: 10.1172/JCI117519. J Clin Invest. 1994. PMID: 7525645 Free PMC article. Review. No abstract available.

8

Engineered protein-small molecule conjugates empower selective enzyme inhibition.

Lewis AK, Harthorn A, Johnson SM, Lobb RR, Hackel BJ. Lewis AK, et al. Among authors: lobb rr. Cell Chem Biol. 2022 Feb 17;29(2):328-338.e4. doi: 10.1016/j.chembiol.2021.07.013. Epub 2021 Aug 6. Cell Chem Biol. 2022. PMID: 34363759

9

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.

Klesmith JR, Su L, Wu L, Schrack IA, Dufort FJ, Birt A, Ambrose C, Hackel BJ, Lobb RR, Rennert PD. Klesmith JR, et al. Among authors: lobb rr. Mol Pharm. 2019 Aug 5;16(8):3544-3558. doi: 10.1021/acs.molpharmaceut.9b00418. Epub 2019 Jul 15. Mol Pharm. 2019. PMID: 31242389

10

Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma.

Singh J, Adams S, Carter MB, Cuervo H, Lee WC, Lobb RR, Pepinsky RB, Petter R, Scott D. Singh J, et al. Among authors: lobb rr. Curr Top Med Chem. 2004;4(14):1497-507. doi: 10.2174/1568026043387520. Curr Top Med Chem. 2004. PMID: 15544540 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results